After beating estimates last quarter by $0.02, rue21
What analysts say:
- Buy, sell, or hold?: Analysts strongly back rue21, with four of six rating it a buy and the remainder rating it a hold. Analysts don't like rue21 as much as competitor Body Central overall. That rating hasn't budged in three months as analysts have remained steady in their opinion of the stock.
- Revenue Forecasts: On average, analysts predict $225.8 million in revenue this quarter. That would represent a rise of 18.8% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.49 per share. Estimates range from $0.48 to $0.50.
What our community says:
CAPS All-Stars are in strong support of the stock, with 91.7% assigning it an "outperform" rating. The majority of Fools agree with the All-Stars, with 74.1% giving it an "outperform" rating. Despite the majority sentiment in favor of rue21, the stock has a middling CAPS rating of three out of five stars.
Rue21's profit has risen year-over-year by an average of 37.2% over the past five quarters.
One final thing: If you want to keep tabs on rue21 movements, and for more analysis on the company, make sure you add it to your Watchlist.